Switching appropriate patients with type 2 diabetes to alogliptin from existing DPP-4 inhibitors: experience and outcomes from three Clinical Commissioning Groups and Local Health Boards

Final version - Takeda supplement

This supplement has been commissioned and funded by Takeda UK Ltd. It has been developed in partnership with Grey Bear Consultancy and published by Guidelines in Practice.

View prescribing information

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage